招银国际发表报告指出,药明生物(02269.HK) 去年新增151个项目,创新高。公司去年赋能7个分子研究服务的全球项目,有权于近期收取约1.4亿美元款项。海外业务方面稳步推进,其爱尔兰生产设施有望于今年收支平衡。管理层亦重申去年指引,预期收入及经调整盈利均增长5%至10%,并对今年收入增长加速充满信心。该行提及,药明生物去年完成工艺性能确认(PPQ)项目77个,按年增长26%,并预期今年将按年...
Source Link招银国际发表报告指出,药明生物(02269.HK) 去年新增151个项目,创新高。公司去年赋能7个分子研究服务的全球项目,有权于近期收取约1.4亿美元款项。海外业务方面稳步推进,其爱尔兰生产设施有望于今年收支平衡。管理层亦重申去年指引,预期收入及经调整盈利均增长5%至10%,并对今年收入增长加速充满信心。该行提及,药明生物去年完成工艺性能确认(PPQ)项目77个,按年增长26%,并预期今年将按年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.